Circadian timing in cancer treatments
- PMID: 20055686
- DOI: 10.1146/annurev.pharmtox.48.113006.094626
Circadian timing in cancer treatments
Abstract
The circadian timing system is composed of molecular clocks, which drive 24-h changes in xenobiotic metabolism and detoxification, cell cycle events, DNA repair, apoptosis, and angiogenesis. The cellular circadian clocks are coordinated by endogenous physiological rhythms, so that they tick in synchrony in the host tissues that can be damaged by anticancer agents. As a result, circadian timing can modify 2- to 10-fold the tolerability of anticancer medications in experimental models and in cancer patients. Improved efficacy is also seen when drugs are given near their respective times of best tolerability, due to (a) inherently poor circadian entrainment of tumors and (b) persistent circadian entrainment of healthy tissues. Conversely, host clocks are disrupted whenever anticancer drugs are administered at their most toxic time. On the other hand, circadian disruption accelerates experimental and clinical cancer processes. Gender, circadian physiology, clock genes, and cell cycle critically affect outcome on cancer chronotherapeutics. Mathematical and systems biology approaches currently develop and integrate theoretical, experimental, and technological tools in order to further optimize and personalize the circadian administration of cancer treatments.
Similar articles
-
[The circadian-timing system: a determinant of drug activity and a target of anticancer treatments].Ann Pharm Fr. 2008 Jun;66(3):175-84. doi: 10.1016/j.pharma.2008.05.003. Ann Pharm Fr. 2008. PMID: 18706346 Review. French.
-
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35. doi: 10.1016/j.addr.2006.11.001. Epub 2007 Jul 4. Adv Drug Deliv Rev. 2007. PMID: 17692427 Review.
-
Chronotherapy and the molecular clock: Clinical implications in oncology.Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):979-1001. doi: 10.1016/j.addr.2010.06.002. Epub 2010 Jun 23. Adv Drug Deliv Rev. 2010. PMID: 20600409 Review.
-
Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics.Cold Spring Harb Symp Quant Biol. 2007;72:465-75. doi: 10.1101/sqb.2007.72.030. Cold Spring Harb Symp Quant Biol. 2007. PMID: 18419306 Review.
-
Cancer chronotherapeutics: experimental, theoretical, and clinical aspects.Handb Exp Pharmacol. 2013;(217):261-88. doi: 10.1007/978-3-642-25950-0_11. Handb Exp Pharmacol. 2013. PMID: 23604483 Review.
Cited by
-
Administration sequences in single-day chemotherapy regimens for breast cancer: a comprehensive review from a practical perspective.Front Oncol. 2024 Sep 30;14:1353067. doi: 10.3389/fonc.2024.1353067. eCollection 2024. Front Oncol. 2024. PMID: 39403333 Free PMC article.
-
The Biological Clock of Liver Metabolism in Metabolic Dysfunction-Associated Steatohepatitis Progression to Hepatocellular Carcinoma.Biomedicines. 2024 Aug 29;12(9):1961. doi: 10.3390/biomedicines12091961. Biomedicines. 2024. PMID: 39335475 Free PMC article. Review.
-
Time-of-day effects of cancer drugs revealed by high-throughput deep phenotyping.Nat Commun. 2024 Aug 22;15(1):7205. doi: 10.1038/s41467-024-51611-3. Nat Commun. 2024. PMID: 39169017 Free PMC article.
-
Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?Br J Cancer. 2024 Sep;131(5):783-796. doi: 10.1038/s41416-024-02704-9. Epub 2024 Jun 4. Br J Cancer. 2024. PMID: 38834742 Free PMC article. Review.
-
Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host.bioRxiv [Preprint]. 2024 May 6:2024.05.03.592418. doi: 10.1101/2024.05.03.592418. bioRxiv. 2024. PMID: 38766060 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
